One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration

Cheryl A. Arcinue, Feiyan Ma, Giulio Barteselli, Lucie Sharpsten, Maria Laura Gomez, William R. Freeman

Research output: Contribution to journalArticle

Abstract

Purpose To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD). Design Retrospective, interventional, consecutive case series. Methods Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept. Results Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti-vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 μm to 269 μm at 6 months (P

Original languageEnglish
Pages (from-to)426-436
Number of pages11
JournalAmerican Journal of Ophthalmology
Volume159
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration'. Together they form a unique fingerprint.

  • Cite this